Protagonist Therapeutics, Inc (PTGX) Financial Statements
Historical financial data — 39 statements covering FY2017–FY2019
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on...
Protagonist Therapeutics, Inc's revenue decreased 95.0% year over year, from $30.9M to $1.6M.
Net income increased 63.8% over the same period, from $-38.9M to $-14.1M.
Over the 2-year period from FY2017 to FY2019, revenue declined by 82% in total.
Operating cash flow grew 66.6% to $-16.7M.
Protagonist Therapeutics, Inc maintains a negative net profit margin of -904.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2017 | $8.8M | $-33.9M | N/A | $-34.4M | $18.0M | $110.4M | N/A | $57.8M |
| Q1 FY2018 | $10.8M+22.8% | $-7.7M | N/A | $-8.2M | $-15.1M | $149.2M | N/A | $114.6M |
| Q2 FY2018 | $11.7M+8.3% | $-8.7M | N/A | $-9.2M | $-15.4M | $137.5M | N/A | $107.7M |
| Q3 FY2018 | $6.1M-47.6% | $-8.7M | N/A | $-9.4M | $-9.3M | $148.9M | N/A | $124.0M |
| Q4 FY2018 | $2.4M-61.5% | $-13.9M | N/A | $-15.4M | $-10.1M | $139.5M | N/A | $112.5M |
| Q1 FY2019 | $1.6M-33.7% | $-14.1M | N/A | $-14.6M | $-16.7M | $132.2M | N/A | $100.8M |
Balance Sheet Summary (Latest Period)
Protagonist Therapeutics, Inc (PTGX) Financial Statements & Revenue History
Protagonist Therapeutics, Inc (PTGX) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $141.86 with a market capitalization of $9. This page provides 39 historical financial statements for Protagonist Therapeutics, Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Protagonist Therapeutics, Inc reported revenue of $2 million, a 95.0% decline from the prior year. The net profit margin of -904.0% indicates the company is currently unprofitable..
PTGX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Protagonist Therapeutics, Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether PTGX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track PTGX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Protagonist Therapeutics, Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of PTGX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use PTGX Financial Data
Investors use Protagonist Therapeutics, Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare PTGX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how PTGX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View PTGX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Protagonist Therapeutics, Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.PTGX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.